FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Regeneron Pharmaceuticals, Inc. patents


      
Recent patent applications related to Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals, Inc. may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals, Inc.-related inventors



Search recent Press Releases: Regeneron Pharmaceuticals, Inc.-related press releases
Count Application # Date Regeneron Pharmaceuticals, Inc. patents (updated weekly) - BOOKMARK this page
12014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
22014021377307/31/14Adam6 mice
32014019655007/17/14Systems and devices for sample handling
42014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
52014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
62014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
72014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
82014017887906/26/14Compositions and methods for modifying cells
92014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
102014015470106/05/14Humanized fc gamma r mice
112014015568906/05/14Methods of modifying genes in eukaryotic cells
122014015744506/05/14Low affinity fcgr deficient mice
132014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
142014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
152014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
162014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
172014013471905/15/14Recombinant cell surface capture proteins
182014013727505/15/14Hybrid light chain mice
192014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
202014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
212014013471905/15/14Recombinant cell surface capture proteins
222014013727505/15/14Hybrid light chain mice
232014013019305/08/14Mice that make vl binding proteins
242014013019405/08/14Mice that make vl binding proteins
252014013019305/08/14Mice that make vl binding proteins
262014013019405/08/14Mice that make vl binding proteins
272014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
282014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
292014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
302014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
312014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
322014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
332014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
342014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
352014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
362014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
372014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
382014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
392014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
402014007297903/13/14Isolating cells expressing secreted proteins
412014007298003/13/14Isolating cells expressing secreted proteins
422014007301003/13/14Methods of modifying eukaryotic cells
432014007558603/13/14Parental cell lines for making cassette-free f1 progeny
442014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
452014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
462014007297903/13/14Isolating cells expressing secreted proteins
472014007298003/13/14Isolating cells expressing secreted proteins
482014007301003/13/14Methods of modifying eukaryotic cells
492014007558603/13/14Parental cell lines for making cassette-free f1 progeny
502014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
512014005690702/27/14Anti-asic1 antibodies and uses thereof
522014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
532014004106802/06/14Methods of modifying eukaryotic cells
542014003333601/30/14Methods of modifying eukaryotic cells
552014003333701/30/14Methods of modifying eukaryotic cells
562014002363701/23/14Methods of modifying eukaryotic cells
572014001722801/16/14Humanized light chain mice
582014001722901/16/14Methods of modifying eukaryotic cells
592014001723801/16/14Methods of modifying eukaryotic cells
602014001769501/16/14Isolating cells expressing secreted proteins
612014001778101/16/14Methods of modifying eukaryotic cells
622014001778201/16/14Methods for modifying eukaryotic cells
632014001852201/16/14Methods of modifying eukaryotic cells
642014002012401/16/14Methods of modifying eukaryotic cells
652014002012501/16/14Methods of modifying eukaryotic cells
662014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
672014001345701/09/14Methods of modifying eukaryotic cells
682013034453812/26/13Human antibodies to the glucagon receptor
692013034010412/19/13Humanized il-7 rodents
702013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
712013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
722013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
732013032326112/05/13Purified antibody composition
742013032378812/05/13Production cell line enhancers
752013032379012/05/13Human lambda light chain mice
762013032379112/05/13Restricted immunoglobulin heavy chain mice
772013032664712/05/13Human lambda light chain mice
782013030967011/21/13Nuclease-mediated targeting with large targeting vectors
792013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
802013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
812013029509711/07/13Human antibodies to fel d1 and methods of use thereof
822013028075810/24/13Fusion polypeptides capable of activating receptors
832013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
842013026657410/10/13Human antibodies to human angiopoietin-like protein 4
852013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
862013025988110/03/13Fusion polypeptides capable of activating receptors
872013026105610/03/13Vegf antagonist formulations
882013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
892013025491109/26/13Adam6 mice
902013024377509/19/13Multispecific antigen-binding molecules and uses thereof
912013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
922013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
932013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
942013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
952013023053109/05/13Human antibodies to clostridium difficile toxins
962013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
972013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
982013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
992013020949208/15/13Anti-tie2 antibodies and uses thereof
1002013021013708/15/13Methods of modifying eukaryotic cells
1012013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1022013020949208/15/13Anti-tie2 antibodies and uses thereof
1032013021013708/15/13Methods of modifying eukaryotic cells
1042013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1052013019587808/01/13Anti-asic1 antibodies and uses thereof
1062013019887908/01/13Humanized universal light chain mice
1072013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1082013019587808/01/13Anti-asic1 antibodies and uses thereof
1092013019887908/01/13Humanized universal light chain mice
1102013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1112013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1122013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1132013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1142013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1152013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1162013018581907/18/13Genetically modified major histocompatibility complex animals
1172013018582007/18/13Genetically modified major histocompatibility complex animals
1182013018582107/18/13Common light chain mouse
1192013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1202013018581907/18/13Genetically modified major histocompatibility complex animals
1212013018582007/18/13Genetically modified major histocompatibility complex animals
1222013018582107/18/13Common light chain mouse
1232013017114907/04/13Anti-angptl3 antibodies and uses thereof
1242013017114907/04/13Anti-angptl3 antibodies and uses thereof
1252013016478606/27/13Fucosylation-deficient cells
1262013016478606/27/13Fucosylation-deficient cells
1272013015731306/20/13High affinity antibodies to human il-6 receptor
1282013016015306/20/13Humanized light chain mice
1292013015731306/20/13High affinity antibodies to human il-6 receptor
1302013016015306/20/13Humanized light chain mice
1312013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1322013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1332013013710105/30/13Methods of modifying eukaryotic cells
1342013013710105/30/13Methods of modifying eukaryotic cells
1352013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1362013012983005/23/13Polymer protein microparticles
1372013013037205/23/13Enhanced expression and stability regions
1382013013038805/23/13Methods of modifying eurakyotic cells
1392013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1402013012983005/23/13Polymer protein microparticles
1412013013037205/23/13Enhanced expression and stability regions
1422013013038805/23/13Methods of modifying eurakyotic cells
1432013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1442013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1452013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1462013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1472013011787305/09/13Humanized il-6 and il-6 receptor
1482013011787305/09/13Humanized il-6 and il-6 receptor
1492013010905305/02/13Genetically modified t cell receptor mice
1502013011161605/02/13Genetically modified major histocompatibility complex mice
1512013011161705/02/13Genetically modified major histocompatibility complex mice
1522013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1532013009628704/18/13Restricted immunoglobulin heavy chain mice
1542013008429704/04/13Anti-erbb3 antibodies and uses thereof
1552013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1562013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1572013007867503/28/13High affinity human antibodies to human il-4 receptor
1582013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1592013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1602013003490202/07/13Fusion polypeptides capable of activating receptors
1612013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1622012032210812/20/12Adam6 mice
1632012032349712/20/12Non-hypergeometric overlap probability
1642012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1652012026035710/11/12Low affinity fcgr deficient mice
1662012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1672012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1682012019230007/26/12Common light chain mouse
1692012017868307/12/12Vegf antagonist formulations
1702012016468806/28/12High affinity human antibodies to human nerve growth factor
1712012013501005/31/12High affinity human antibodies to human il-4 receptor
1722012012867905/24/12Human antibodies to the glucagon receptor
1732012011464505/10/12Use of il-1 antagonists to treat pseudogout
1742012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1752012011466505/10/12Human antibodies to human rankl
1762012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1772012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1782012010103504/26/12Vegf antagonist formulations
1792012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1802012009657204/19/12Mice that make vl binding proteins
1812012008792904/12/12Vegf antagonist formulations for intravitreal administration
1822012008300004/05/12Neuropeptide release assay for sodium channels
1832012007679003/29/12Anti-cd48 antibodies and uses thereof
1842012007086103/22/12Human lambda light chain mice
1852012007300403/22/12Hybrid light chain mice
1862012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1872012005207203/01/12High affinity human antibodies to human il-4 receptor
1882012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1892012002140901/26/12Common light chain mouse
1902012001496801/19/12Stabilized formulations containing anti-ngf antibodies
1912012000369701/05/12High affinity antibodies to human il-6 receptor
1922011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
1932011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
1942011030796612/15/11Mice expressing human voltage-gated sodium channels
1952011030796812/15/11Production of fertile xy animals from xy es cells
1962011029363012/01/11Antibodies to human gdf8
1972011028337611/17/11Methods of modifying eukaryotic cells
1982011026918711/03/11High affinity human antibodies to human il-18 receptor
1992011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
2002011025655610/20/11Humanized fcgr mice
2012011025658710/20/11High affinity human antibodies to human nerve growth factor
2022011025760110/20/11Vegf antagonist formulations for intravitreal administration
2032011025871010/20/11Methods of modifying eukaryotic cells
2042011019545408/11/11Common light chain mouse
2052011018917608/04/11Methods of treating diseases with dll4 antagonists
2062011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2072011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2082011016565007/07/11Fusion polypeptides capable of activating receptors
2092011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2102011015090506/23/11Human antibodies to human delta like ligand 4
2112011015451206/23/11Humanized fc gamma r mice
2122011014593706/16/11Mice that make heavy chain antibodies
2132011010479905/05/11Multifunctional alleles
2142011008168104/07/11Human antibodies to human cd20 and method of using thereof
2152011006590203/17/11High affinity human antibodies to pcsk9
2162011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2172011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2182011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2192011002728602/03/11High affinity human antibodies to human angiopoietin-2
2202011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2212011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2222011000837401/13/11Use of il-1 antagonists to treat gout
2232010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2242010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2252010031662712/16/10Human antibodies to human il-6 receptor
2262010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2272010030443612/02/10Fucosylation-deficient cells
2282010029110711/18/10High affinity human antibodies to human il-4 receptor
2292010029162611/18/10Enhanced expression and stability regions
2302010027993311/04/10Vegf antagonist formulations
2312010023380309/16/10Fusion polypeptides capable of activating receptors
2322010022178209/02/10Modified chimeric polypeptides with improved pharmacokinetic properties
2332010016676807/01/10High affinity human antibodies to pcsk9
2342010012981705/27/10Identifying germline competent embryonic stem cells
2352010011192105/06/10Use of il-1 antagonists to treat gout
2362010008763204/08/10Vegf-binding fusion proteins and therapeutic uses thereof
2372010007590303/25/10Lyophilized vegf antagonist formulations for intravitreal administration
2382010004725402/25/10High affinity human antibodies to human il-4 receptor
2392010004233002/18/10Non-hypergeometric overlap probability
2402010003483302/11/10High affinity human antibodies to human il-18 receptor
2412010002147601/28/10High affinity human antibodies to human il-4 receptor
2422009028584111/19/09Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
2432009027188410/29/09Es cell-derived mice from diploid host embryo injection
2442009024619910/01/09Therapeutic methods for inhibiting tumor growth with dll4 antagonists
2452009017586407/09/09Igf-1 and igf-2 chimeric polypeptides and therapeutic uses thereof
2462009016290106/25/09Inducible eukaryotic expression system
2472009015589906/18/09Modified chimeric polypeptides with improved pharmacokinetic properties
2482009015649206/18/09Methods of using il-1 antagonists to treat autoinflammatory disease
2492009014235406/04/09Human antibodies to human delta like ligand 4


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo